Will pharmacogenomic testing become a routine part of clinical care?

Some adverse drug events are a predictable consequence of therapeutic, especially dosing failures. Idiosyncratic toxicities, on the other hand, are much less predictable and much more insidious. Pharmacogenomics is a powerful tool that can reveal some of these vulnerabilities before toxicity occurs or, if performed after the fact, can explain the cause of an adverse drug event that has already happened. Clinical trials cannot detect all adverse drug events due to the limited population in which the drugs are being

Read More »

Utilizing pharmacogenomic testing to ensure effective therapy

Some medications are administered as prodrugs that need to be metabolized in the active form by the body. An example of such a drug is codeine. It undergoes biotransformation into morphine by CYP2D6. Patients who transform codeine faster who are referred to as ultrarapid metabolizers, transform codeine into morphine so fast that they can develop opioid toxicity. On the other hand, poor metabolizers would not be able to produce enough active moiety, thereby making the drug ineffective. One such example

Read More »

Subscribe to our newsletter